Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Phytother Res ; 34(5): 1166-1174, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-31833107

RESUMO

Berberine (BBR), a small alkaloid, is used as a hypoglycemic agent in China. Stachyose (Sta), a Rehmannia glutinosa oligosaccharide, acts as a prebiotic. This study aimed to evaluate whether BBR combined with Sta produced better glycometabolism than BBR alone, and explored the effects on gut microbiota and metabolomics. Type-2 diabetic db/db mice were administered BBR (100 mg/kg), Sta (200 mg/kg), or both by gavage once daily. Glucose metabolism, the balance of α- and ß-cells, and mucin-2 expression were ameliorated by combined treatment of BBR and Sta, with stronger effects than upon treatment with BBR alone. The microbial diversity and richness were altered after combined treatment and after treatment with BBR alone. The abundance of Akkermansia muciniphila was increased by combined treatment compared to treatment with BBR alone, while the levels of the metabolite all-trans-heptaprenyl diphosphate were decreased and the levels of fumaric acid were increased, which both showed a strong correlation with A. muciniphila. In summary, BBR combined with Sta produced better glycometabolism than BBR alone through modulating gut microbiota and fecal metabolomics, and may aid in the development of a novel pharmaceutical strategy for treating Type 2 diabetes mellitus.


Assuntos
Berberina/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Fezes/química , Microbioma Gastrointestinal/efeitos dos fármacos , Metabolômica/métodos , Oligossacarídeos/uso terapêutico , Animais , Berberina/farmacologia , Masculino , Camundongos , Oligossacarídeos/farmacologia
2.
Mitochondrial DNA B Resour ; 3(1): 125-126, 2018 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-33474090

RESUMO

Prunella vulgaris L. is an important medicinal herb widely used in China and western countries. Its natural distribution occurs in various habitats throughout northern hemisphere. In present study, we assembled and characterized its whole chloroplast (cp) genome based on Illumina pair-end sequencing data. The complete chloroplast genome size is 156,132 bp. It contained 134 genes, including 89 protein-coding genes, 37 tRNA genes, and 8 rRNA genes. 8 gene species had two copies. The overall GC content of this genome was 37.9%. A further phylogenomic analysis of Lamiaceae, including 29 taxa, was conducted for the placement of P. vulgaris.

3.
Chin J Nat Med ; 13(8): 578-87, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26253490

RESUMO

Diosgenin, a well-known steroid sapogenin derived from plants, has been used as a starting material for production of steroidal hormones. The present review will summarize published literature concerning pharmacological potential of diosgenin, and the underlying mechanisms of actions. Diosgenin has shown a vast range of pharmacological activities in preclinical studies. It exhibits anticancer, cardiovascular protective, anti-diabetes, neuroprotective, immunomodulatory, estrogenic, and skin protective effects, mainly by inducing apoptosis, suppressing malignant transformation, decreasing oxidative stress, preventing inflammatory events, promoting cellular differentiation/proliferation, and regulating T-cell immune response, etc. It interferes with cell death pathways and their regulators to induce apoptosis. Diosgenin antagonizes tumor metastasis by modulating epithelial-mesenchymal transition and actin cytoskeleton to change cellular motility, suppressing degradation of matrix barrier, and inhibiting angiogenesis. Additionally, diosgenin improves antioxidant status and inhibits lipid peroxidation. Its anti-inflammatory activity is through inhibiting production of pro-inflammatory cytokines, enzymes and adhesion molecules. Furthermore, diosgenin drives cellular growth/differentiation through the estrogen receptor (ER) cascade and transcriptional factor PPARγ. In summary, these mechanistic studies provide a basis for further development of this compound for pharmacotherapy of various diseases.


Assuntos
Anti-Inflamatórios/farmacologia , Antineoplásicos Fitogênicos/farmacologia , Antioxidantes/farmacologia , Diosgenina/farmacologia , Fitoestrógenos/farmacologia , Extratos Vegetais/farmacologia , Animais , Proliferação de Células/efeitos dos fármacos , Humanos , Mediadores da Inflamação/metabolismo , Estresse Oxidativo/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA